These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Photophysical and biological investigation of novel luminescent Ru(II)-polypyridyl-1,8-naphthalimide Tröger's bases as cellular imaging agents. Elmes RB; Erby M; Bright SA; Williams DC; Gunnlaugsson T Chem Commun (Camb); 2012 Mar; 48(20):2588-90. PubMed ID: 22293955 [TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Anticancer Studies of a Mohan B; Estalayo-Adrián S; Umadevi D; la Cour Poulsen B; Blasco S; McManus GJ; Gunnlaugsson T; Shanmugaraju S Inorg Chem; 2022 Aug; 61(30):11592-11599. PubMed ID: 35857283 [TBL] [Abstract][Full Text] [Related]
14. π-Expansive Heteroleptic Ruthenium(II) Complexes as Reverse Saturable Absorbers and Photosensitizers for Photodynamic Therapy. Wang L; Yin H; Jabed MA; Hetu M; Wang C; Monro S; Zhu X; Kilina S; McFarland SA; Sun W Inorg Chem; 2017 Mar; 56(6):3245-3259. PubMed ID: 28263079 [TBL] [Abstract][Full Text] [Related]
15. Design of a Tris-Heteroleptic Ru(II) Complex with Red-Light Excitation and Remarkably Improved Photobiological Activity. Li S; Zhao J; Wang X; Xu G; Gou S; Zhao Q Inorg Chem; 2020 Aug; 59(15):11193-11204. PubMed ID: 32702972 [TBL] [Abstract][Full Text] [Related]
16. Physicochemical and biological interactions between cerium oxide nanoparticles and a 1,8-naphthalimide derivative. Pulido-Reyes G; Martín E; Gu Coronado JL; Leganes F; Rosal R; Fernández-Piñas F J Photochem Photobiol B; 2017 Jul; 172():61-69. PubMed ID: 28527428 [TBL] [Abstract][Full Text] [Related]
17. Critical Overview of the Use of Ru(II) Polypyridyl Complexes as Photosensitizers in One-Photon and Two-Photon Photodynamic Therapy. Heinemann F; Karges J; Gasser G Acc Chem Res; 2017 Nov; 50(11):2727-2736. PubMed ID: 29058879 [TBL] [Abstract][Full Text] [Related]
18. A Ruthenium(II) N-Heterocyclic Carbene (NHC) Complex with Naphthalimide Ligand Triggers Apoptosis in Colorectal Cancer Cells via Activating the ROS-p38 MAPK Pathway. Dabiri Y; Schmid A; Theobald J; Blagojevic B; Streciwilk W; Ott I; Wölfl S; Cheng X Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544880 [TBL] [Abstract][Full Text] [Related]
19. Fluorescent organometallic rhodium(I) and ruthenium(II) metallodrugs with 4-ethylthio-1,8-naphthalimide ligands: Antiproliferative effects, cellular uptake and DNA-interaction. Streciwilk W; Terenzi A; Cheng X; Hager L; Dabiri Y; Prochnow P; Bandow JE; Wölfl S; Keppler BK; Ott I Eur J Med Chem; 2018 Aug; 156():148-161. PubMed ID: 30006161 [TBL] [Abstract][Full Text] [Related]
20. Potential anticancer agent for selective damage to mitochondria or lysosomes: Naphthalimide-modified fluorescent biomarker half-sandwich iridium (III) and ruthenium (II) complexes. Ma W; Zhang S; Tian Z; Xu Z; Zhang Y; Xia X; Chen X; Liu Z Eur J Med Chem; 2019 Nov; 181():111599. PubMed ID: 31408807 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]